UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 9, 2017
Intermolecular, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
001-35348 |
20-1616267 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
3011 N. First Street San Jose, California |
|
95134 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
(408) 582-5700 |
|
(Registrant’s Telephone Number, Including Area Code) |
|
N/A |
|
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
◻ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
◻ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
◻ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
◻ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 8.01 OTHER EVENTS
On October 9, 2017, Intermolecular, Inc. received a letter dated October 9, 2017 from the NASDAQ Listing Qualifications notifying the Company that it has regained compliance with the requirement of the NASDAQ Global Select Market to maintain a minimum bid price of $1.00 per share, as set forth in NASDAQ Listing Rule 5450 (a) (1).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
INTERMOLECULAR, INC. |
||
|
|
|||
|
Date: October 09, 2017 |
By: |
|
/s/ Bill Roeschlein |
|
|
|
|
Bill Roeschlein |
|
|
|
|
Chief Financial Officer |